ADHD (Attention-Deficit/Hyperactivity Disorder)

ADHD — scientific infographic poster

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology (Neurobiology)
  4. Etiology and Risk Factors
  5. DSM-5 Diagnostic Subtypes
  6. Clinical Presentation
  7. Diagnosis
  8. Treatment
  9. Comorbidities
  10. Complications
  11. Prognosis
  12. Research Papers and References
  13. Featured Videos

1. Overview

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder worldwide, affecting an estimated 5–10% of children and 2.5–4% of adults. It is characterized by three core symptom domains: inattention, hyperactivity, and impulsivity — impairing functioning across school, work, relationships, and daily life. ADHD is not a character flaw or a failure of will; it is a brain-based condition with robust neurobiological and genetic foundations.

The DSM-5 (2013) reclassified ADHD from the chapter on "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence" into the new Neurodevelopmental Disorders chapter — a critical shift that acknowledges ADHD as a lifelong condition rather than a childhood problem that children outgrow. In reality, 60–70% of those diagnosed in childhood continue to meet criteria in adulthood, and millions more carry significant residual impairment even when they no longer meet full diagnostic thresholds.

A persistent myth is that ADHD primarily affects boys and resolves by adolescence. In fact, females are systematically underdiagnosed, often presenting with the predominantly inattentive subtype — characterized by daydreaming, disorganization, and forgetfulness rather than the visible hyperactivity more commonly observed in males. Girls and women frequently develop sophisticated masking behaviors that conceal their struggles, delaying diagnosis by years or decades and allowing anxiety, depression, and low self-esteem to accumulate in the interim.

With appropriate treatment — combining behavioral strategies, environmental accommodations, and when indicated, medication — individuals with ADHD can and do thrive. ADHD is associated with many strengths when well-managed, including creativity, hyperfocus on areas of deep interest, high energy, and entrepreneurial thinking.

2. Epidemiology

ADHD is one of the most studied psychiatric conditions in children. The US prevalence among children is approximately 9.4% based on CDC data from 2016, translating to roughly 6.1 million children aged 2–17. Among US adults, the 12-month prevalence is approximately 4.4% (Kessler et al., 2006), suggesting a significant treatment gap — the majority of adults with ADHD have never been diagnosed or treated.

Globally, a landmark 2007 meta-analysis by Polanczyk et al. estimated a pooled worldwide prevalence of 5.29% in children, with a 2014 update confirming stability of rates over three decades, arguing against a true epidemic — variation in prevalence across countries largely reflects differences in diagnostic criteria and assessment methods, not true biological differences in incidence.

The male-to-female ratio in diagnosed populations is approximately 2–3:1, but population-based and genetic studies suggest the true ratio is closer to 1.5:1. The diagnostic gap reflects referral bias: hyperactive boys are more likely to be brought to clinical attention. Peak age of diagnosis is 7–10 years. Significant racial and ethnic disparities exist in diagnosis rates in the United States, with Black and Hispanic children historically underdiagnosed relative to non-Hispanic white children, a gap that reflects systemic inequities in access to diagnostic evaluation rather than true differences in prevalence.

The adult treatment gap is substantial. Only about 25% of adults who meet criteria for ADHD receive treatment. Many adults are diagnosed only after their own child receives a diagnosis, prompting retrospective recognition of lifelong symptoms. Late diagnosis — while sometimes distressing — is frequently experienced as profoundly validating.

3. Pathophysiology (Neurobiology)

Dopamine and Norepinephrine Dysregulation

The core neurobiological mechanism of ADHD involves dysfunction in catecholamine signaling — specifically, dopamine (DA) and norepinephrine (NE) — within the prefrontal cortex (PFC). The PFC governs executive functions including working memory, attention regulation, response inhibition, and cognitive flexibility. As described in the seminal catecholamine theory of ADHD developed by Amy Arnsten, optimal PFC function requires a narrow range of DA and NE stimulation — too little or too much impairs the "tuning" of PFC networks, weakening signal relative to noise. In ADHD, this balance is disrupted, impairing the PFC's ability to sustain focused attention, suppress distractions, and regulate impulses.

Genetic Associations

Twin studies estimate ADHD heritability at 70–80%, making it one of the most heritable psychiatric conditions. Key genetic associations include:

ADHD has a polygenic architecture; no single gene accounts for more than a small fraction of risk. Rare copy number variants (CNVs) including deletions at 22q11.2 and 16p13.11 are enriched in ADHD.

Executive Function Deficits

Neuropsychological research identifies consistent deficits in:

Neuroimaging Findings

The landmark Shaw et al. (2007) PNAS study using longitudinal MRI in 446 children demonstrated that ADHD is characterized by a 3–5 year delay in cortical maturation — most significantly in prefrontal regions — rather than a fixed structural deficit. This finding reframes ADHD as a developmental lag rather than a static brain difference, consistent with the clinical observation that some children do "grow out" of symptoms as their cortex catches up.

Additional structural findings include:

Default Mode Network Dysfunction

In individuals without ADHD, the Default Mode Network (DMN) — active during rest and self-referential thinking — is reliably suppressed when a task demands focused attention. In ADHD, this suppression fails: the DMN remains active during tasks, generating the "mind wandering" and intrusive self-referential thoughts that characterize inattentive symptoms. Abnormal DMN–task-positive network anticorrelation is among the most replicated fMRI findings in ADHD.

4. Etiology and Risk Factors

Genetic Factors

Prenatal Exposures

Perinatal and Early Life Factors

Factors That Do NOT Cause ADHD

Several widely circulated myths about ADHD etiology deserve explicit correction:

5. DSM-5 Diagnostic Subtypes

DSM-5 defines three presentations of ADHD based on the predominant symptom cluster over the past 6 months. Note that in DSM-5 terminology, these are called "presentations" rather than "subtypes" because they can shift over time.

Predominantly Inattentive Presentation (ADHD-PI)

Requires 6 or more of the following inattention symptoms (5 for adults age 17 and older):

  1. Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities
  2. Often has difficulty sustaining attention in tasks or play activities
  3. Often does not seem to listen when spoken to directly
  4. Often does not follow through on instructions and fails to finish schoolwork or chores
  5. Often has difficulty organizing tasks and activities
  6. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort
  7. Often loses things necessary for tasks or activities (e.g., school materials, keys, wallet)
  8. Is often easily distracted by extraneous stimuli
  9. Is often forgetful in daily activities

Predominantly Hyperactive-Impulsive Presentation (ADHD-PHI)

Requires 6 or more of the following hyperactivity-impulsivity symptoms (5 for adults age 17 and older):

  1. Often fidgets with or taps hands or feet, or squirms in seat
  2. Often leaves seat in situations when remaining seated is expected
  3. Often runs about or climbs in situations where it is inappropriate (in adolescents/adults: may be limited to feeling restless)
  4. Often unable to play or engage in leisure activities quietly
  5. Is often "on the go," acting as if "driven by a motor"
  6. Often talks excessively
  7. Often blurts out an answer before a question has been completed
  8. Often has difficulty waiting his or her turn
  9. Often interrupts or intrudes on others (e.g., butts into conversations or games)

Combined Presentation (ADHD-C)

Requires 6 or more symptoms from both inattention and hyperactivity-impulsivity lists. This is the most common presentation in children referred to clinical settings.

Cross-Cutting Diagnostic Requirements

Severity Specifiers

6. Clinical Presentation

Children

In school-age children, ADHD commonly presents with:

Girls and Women

Females with ADHD are disproportionately diagnosed with the predominantly inattentive presentation and often go unrecognized because they do not display the overt hyperactivity that triggers referrals in boys. Key features include:

Adults

In adults, hyperactivity becomes more internalized ("inner restlessness"), and the clinical picture often centers on:

7. Diagnosis

Clinical Assessment

ADHD is a clinical diagnosis based on a comprehensive evaluation. There is no definitive biomarker, blood test, or brain scan that diagnoses ADHD. The evaluation should include a structured psychiatric interview, review of developmental history, reports from multiple informants (parent, teacher, partner), and validated rating scales.

Validated Rating Scales

Differential Diagnosis and Rule-Outs

Multiple conditions can mimic or co-occur with ADHD and must be assessed:

Adjunctive Diagnostic Tools

8. Treatment

Behavioral Therapy First (Children Under 6)

The American Academy of Pediatrics (AAP) 2019 Clinical Practice Guideline recommends behavior therapy as the first-line treatment for children under 6, before considering medication. Parent Training in Behavior Management (PTBM) is the most evidence-based approach — parents learn contingency management techniques, consistent limit-setting, and positive reinforcement strategies. Preschool-age children are particularly responsive to behavioral interventions and at greater risk of stimulant side effects.

For children aged 6 and older, and adolescents and adults, the guidelines recommend a combined behavioral + pharmacological approach as most effective, with either alone being superior to no treatment.

Stimulant Medications (First-Line for Age 6+)

Stimulants are the most extensively studied medications in child psychiatry. They are effective in approximately 70–80% of children and produce large effect sizes (Cohen's d approximately 0.8–1.0) in reducing core ADHD symptoms.

Methylphenidate-Based Stimulants

Amphetamine-Based Stimulants

Common stimulant side effects: decreased appetite (especially at lunchtime), delayed sleep onset, increased heart rate and blood pressure, mild growth suppression (1–2 cm over years), rebound irritability as medication wears off. Side effects are generally dose-dependent and manageable with timing adjustments or dose reduction.

Non-Stimulant Medications

Non-stimulants are slower-onset (weeks to reach full effect) and generally have smaller effect sizes than stimulants, but are valuable for patients who do not tolerate stimulants, have significant anxiety, cardiovascular concerns, or substance abuse history, or who require 24-hour coverage without stimulant rebound.

Behavioral and Psychosocial Treatments

Educational Accommodations

9. Comorbidities

ADHD rarely presents in isolation. The majority of individuals with ADHD have at least one comorbid condition, with many carrying two or more. Comorbidities are not complications of ADHD per se but reflect shared neurobiological substrates and the psychological burden of living with an unmanaged condition.

10. Complications

11. Prognosis

ADHD is a lifelong condition for the majority of those diagnosed in childhood. 60–70% of children with ADHD continue to meet full diagnostic criteria in adulthood, and an additional 10–15% carry significant residual impairment below the diagnostic threshold. The functional trajectory is strongly modulated by whether and when treatment is received.

With treatment, outcomes are substantially improved across all domains: academic achievement, employment stability, relationship quality, reduced accident rates, and lower rates of substance abuse. Multimodal treatment — combining behavioral interventions, appropriate pharmacotherapy, and educational accommodations — produces the best outcomes. The landmark MTA (Multimodal Treatment Study of Children with ADHD) demonstrated that combined treatment produced superior outcomes to behavioral therapy alone and to medication alone in short-term follow-up.

Without treatment, the cumulative toll is significant. Adults with untreated ADHD have higher rates of unemployment, divorce, substance abuse, incarceration, accidental injury, and premature death. They are also more likely to have multiple failed treatment attempts for depression or anxiety that were actually manifestations of unrecognized ADHD.

Predictors of poorer outcome include: comorbid conduct disorder, lower socioeconomic status, high family conflict, early-onset substance use, and failure to receive adequate treatment. Predictors of better outcome include: above-average intelligence, good family support, access to behavioral therapy and school accommodations, appropriate stimulant treatment, and early diagnosis.

A critical public health message is that stimulant treatment in childhood does not cause later substance abuse — the evidence consistently shows the opposite: stimulant-treated individuals have lower rates of adult SUD than untreated ADHD controls. This myth deters many families from pursuing treatment, resulting in preventable harm.

Females diagnosed and treated late face a particularly important prognostic consideration: by the time of diagnosis, many have accumulated years of secondary anxiety, depression, and self-blame. These conditions require treatment in their own right; ADHD treatment alone may not fully reverse the psychological damage of late recognition.

12. Research Papers and References

Key Research Papers

  1. Faraone SV, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2021;7(1):2. PMID: 33479224. DOI: 10.1038/s41572-021-00260-3
  2. Polanczyk GV, et al. ADHD prevalence estimates across three decades: an updated systematic review. Int J Epidemiol. 2014;43(2):434–442. PMID: 24464188. DOI: 10.1093/ije/dyt261
  3. Shaw P, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. PNAS. 2007;104(49):19649–19654. PMID: 18024590. DOI: 10.1073/pnas.0707741104
  4. Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89–99. PMID: 21489408. DOI: 10.1016/j.biopsych.2011.01.027
  5. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237–248. PMID: 16023516. DOI: 10.1016/S0140-6736(05)66915-2
  6. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–499. PMID: 22976615. DOI: 10.1007/s13311-012-0135-8
  7. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. PMID: 31570648. DOI: 10.1542/peds.2019-2528
  8. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. PMID: 30097390. DOI: 10.1016/S2215-0366(18)30269-4
  9. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States. Am J Psychiatry. 2006;163(4):716–723. PMID: 16585449. DOI: 10.1176/appi.ajp.163.4.716
  10. Molina BS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484–500. PMID: 19318991. DOI: 10.1097/CHI.0b013e31819c23d0
  11. Franke B, et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry. 2012;17(10):960–987. PMID: 22105624. DOI: 10.1038/mp.2011.138
  12. Lichtenstein P, et al. Medication for attention deficit–hyperactivity disorder and criminality. NEJM. 2012;367(21):2006–2014. PMID: 23171097. DOI: 10.1056/NEJMoa1203241

Back to Table of Contents

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents